1. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
2. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
3. Administration. (USFaD).FDA Drug Safety Communication: FDA revises label of diabetes drug canagliflozin (Invokana Invokamet) to include updates on bone fracture risk and new information on decreased bone mineral density. Accessed September 10 2015.
4. Administration. (USFaD).Drug Safety Communication: FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana Invokamet Invokamet XR). Accessed May 16 2017.
5. Administration. (FaD).FDA Drug Safety Communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. Accessed December 4 2015.